Celyad gains on CAR T deal amendment

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.).

Celyad gained €2.97 (11%) to €31.37 in Brussels on Friday, and added $5.68 (18%) to $38.05 in New York...